19:49 , Jun 7, 2019 |  BioCentury  |  Emerging Company Profile

insitro: machine learning with designated data

Just 12 months after announcing the launch of insitro, AI veteran and CEO Daphne Koller has led the drug discovery and machine learning company to a series A round of over $100 million and a...
22:43 , Jun 3, 2019 |  BC Extra  |  Company News

June 3 Company Quick Takes: EU pharmas form consortium to predict late-stage success; plus Lilly/Atomwise, Gilead/HitGen, Emergent and more

EU public-private consortium aims to better predict late-stage compounds  A group of pharmaceutical, technology and academic institutions formed a consortium to use machine learning on chemical libraries of 10 pharmaceutical companies to develop a platform...
19:42 , May 2, 2019 |  BC Extra  |  Financial News

May 2 Financial Quick Takes: Magenta, Clovis, Atomwise

Magenta follow-on comes with haircut  Stem cell transplant company Magenta Therapeutics Inc. (NASDAQ:MGTA) raised $56.3 million in a follow-on underwritten by J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow. At $13.25 per share, the price...
23:44 , Apr 18, 2019 |  BC Extra  |  Company News

Three steps forward, one step back for AI drug discovery

Two AI drug discovery and development deals this week, and new hits announced from an existing collaboration, show sustained momentum in the space despite news that IBM will stop seeking partnerships for its Watson for...
21:35 , Apr 17, 2019 |  BC Extra  |  Preclinical News

Atomwise unveils Chagas disease compounds from AIMS program

Atomwise has revealed the first hit identifications by two of its AIMS program collaborators, including compounds against an unexploited target for Chagas disease, for which there are few therapies. On Tuesday, Atomwise Inc. (San Francisco,...
18:43 , Jan 18, 2019 |  BC Week In Review  |  Company News

Atomwise, Charles River partnership brings CRO model to AI

Atomwise Inc. (San Francisco, Calif.) is scaling up delivery of its artificial intelligence-based medicinal chemistry technology through a partnership with Charles River Laboratories International Inc. (NYSE:CRL) announced Jan. 11. The alliance gives drug developers a...
00:45 , Jan 12, 2019 |  BC Extra  |  Company News

Atomwise, Charles River partnership brings CRO model to AI

Atomwise Inc. (San Francisco, Calif.) is scaling up delivery of its artificial intelligence-based medicinal chemistry technology through a partnership with Charles River Laboratories International Inc. (NYSE:CRL) announced Friday. The alliance gives drug developers a CRO...
20:56 , Jan 3, 2019 |  BC Innovations  |  Emerging Company Profile

Auransa’s AI-predicted pipeline

Auransa Inc. has built a predictive AI-based discovery engine that analyzes patient-derived data to identify and develop the right compound for each patient subpopulation in less time than traditional discovery methods. “The engine unbiasedly reveals...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
16:43 , Sep 21, 2018 |  BC Week In Review  |  Company News

Atomwise identifying small molecules for Pfizer

Atomwise Inc. (San Francisco, Calif.) partnered with Pfizer Inc. (NYSE:PFE) to use its AI platform to identify small molecule candidates for up to three target proteins from Pfizer. Atomwise will receive an undisclosed technology access...